Table 1 Characteristics of patients with and without axillary lymph node metastasis

Age (years)

51.85 ± 10.68

49.91 ± 11.13

0.191^a

52.04 ± 10.71

51.13 ± 11.87

0.620^a

51.39 ± 10.78

47.10 ± 8.74

0.080^a

Maximum diameter (cm)

2.74 ± 1.03

3.63 ± 1.59

 < 0.001^a

2.73 ± 1.04

3.53 ± 1.54

 < 0.001^a

2.78 ± 1.01

3.87 ± 1.70

0.003^a

Minimum diameter (cm)

1.80 ± 0.63

2.30 ± 1.02

 < 0.001^a

1.80 ± 0.63

2.28 ± 1.05

0.001^a

1.81 ± 0.65

2.33 ± 0.99

0.014^a

Effective diameter (cm)

2.27 ± 0.78

2.97 ± 1.22

 < 0.001^a

2.26 ± 0.79

2.91 ± 1.20

 < 0.001^a

2.30 ± 0.77

3.10 ± 1.27

0.003^a

Perineural invasion

0.542^b

0.479^b

1.000^b

 Negative

105(95.45%)

102(93.58%)

74(96.10%)

70(92.11%)

31(93.94%)

32(96.97%)

 Positive

5(4.55%)

7(6.42%)

3(3.90%)

6(7.89%)

2(6.06%)

1(3.03%)

LVI

0.014^b

0.034^b

0.202^b

 Negative

93(84.55%)

77(70.64%)

64(83.12%)

52(68.42%)

29(87.88%)

25(75.76%)

 Positive

17(15.45%)

32(29.36%)

13(16.88%)

24(31.58%)

4(12.12%)

8(24.24%)

ER

0.959^b

0.542^b

0.306^b

 Negative

40(36.36%)

40(36.70%)

30(38.96%)

26(34.21%)

10(30.30%)

14(42.42%)

 Positive

70(63.64%)

69(63.30%)

47(61.04%)

50(65.79%)

23(69.70%)

19(57.58%)

PR

0.453^b

0.939^b

0.138^b

 Negative

56(50.91%)

61(55.96%)

41(53.25%)

40(52.63%)

15(45.45%)

21(63.64%)

 Positive

54(49.09%)

48(44.04%)

36(46.75%)

36(47.37%)

18(54.55%)

12(36.36%)

HER-2

0.848^b

0.764^b

0.438^b

 Negative

76(69.09%)

74(67.89%)

53(68.83%)

54(71.05%)

23(69.70%)

20(60.61%)

 Positive

34(30.91%)

35(32.11%)

24(31.17%)

22(28.95%)

10(30.30%)

13(39.39%)

Ki-67

0.038^b

0.117^b

0.159^b

 < 20%

37(33.64%)

23(21.10%)

26(33.77%)

17(22.37%)

11(33.33%)

6(18.18%)

 ≥ 20%

73(66.36%)

86(78.90%)

51(66.23%)

59(77.63%)

22(66.67%)

27(81.82%)

T stage

 < 0.001^c

 < 0.001^c

0.028^c

 T1

49(44.55%)

21(19.27%)

35(45.45%)

14(18.42%)

14(42.42%)

7(21.21%)

 T2

58(52.73%)

70(64.22%)

41(53.25%)

51(67.11%)

17(51.52%)

19(57.58%)

 T3

1(0.91%)

11(10.09%)

0(0.00%)

5(6.58%)

1(3.03%)

6(18.18%)

 T4

2(1.82%)

7(6.42%)

1(1.30%)

6(7.89%)

1(3.03%)

1(3.03%)

M stage

0.671^b

0.239^b

1.000^b

 M0

108(98.18%)

105(96.33%)

77(100.00%)

73(96.05%)

31(93.94%)

32(96.97%)

 M1

2(1.82%)

4(3.67%)

0(0.00%)

3(3.95%)

2(6.06%)

1(3.03%)

AJCC stage

0.241^c

0.615^c

0.165^c

 I

22(20.00%)

12(11.01%)

15(19.48%)

10(13.16%)

7(21.21%)

2(6.06%)

 II

46(41.82%)

47(43.12%)

32(41.56%)

33(43.42%)

14(42.42%)

14(42.42%)

 III

18(16.36%)

30(27.52%)

12(15.58%)

19(25.00%)

6(18.18%)

11(33.33%)

 IV

24(21.82%)

20(18.35%)

18(23.38%)

14(18.42%)

6(18.18%)

6(18.18%)

MRI parameters

 K^trans (min⁻¹)

0.22 ± 0.12

0.19 ± 0.12

0.058^a

0.22 ± 0.11

0.19 ± 0.11

0.047^a

0.21 ± 0.14

0.20 ± 0.14

0.598^a

 K_ep (min⁻¹)

0.82 ± 0.25

0.86 ± 0.22

0.269^a

0.84 ± 0.24

0.85 ± 0.23

0.756^a

0.79 ± 0.29

0.88 ± 0.20

0.144^a

 V_e

0.27 ± 0.13

0.22 ± 0.12

0.006^a

0.27 ± 0.12

0.22 ± 0.11

0.022^a

0.29 ± 0.15

0.23 ± 0.15

0.115^a

 W-in (min⁻¹)

0.57 ± 0.21

0.60 ± 0.27

0.368^a

0.56 ± 0.19

0.59 ± 0.27

0.365^a

0.59 ± 0.26

0.61 ± 0.28

0.775^a

 W-out (min⁻¹)

-0.01 ± 0.02

-0.02 ± 0.02

0.002^a

-0.01 ± 0.02

-0.02 ± 0.02

0.009^a

-0.01 ± 0.02

-0.02 ± 0.02

0.081^a

 TTP (min)

0.67 ± 0.19

0.67 ± 0.20

0.983^a

0.67 ± 0.19

0.68 ± 0.20

0.803^a

0.67 ± 0.21

0.65 ± 0.21

0.698^a

 ADC (× 10 ⁻³ mm²/s)

0.87 ± 0.15

0.84 ± 0.13

0.158^a

0.87 ± 0.14

0.84 ± 0.15

0.239^a

0.86 ± 0.17

0.83 ± 0.09

0.447^a